TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04608110: A Phase 1, Multi-center, Open-label, Uncontrolled, Dose-escalation Study to Evaluate the Pharmacokinetics of ASTX030 in Patients With Myelodysplastic Syndrome (MDS)

Sponsor: Taiho Pharmaceutical Co., Ltd. · Phase: PHASE1 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 59 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$3,747,616

Rescue Site Savings

+$2,483,360

Unlock Full NCT04608110 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04608110 Rescue Dossier →